Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Capricor Therapeutics' stock soared 500% after its drug met key trial goals, reversing an earlier FDA setback.
Capricor Therapeutics' stock surged up to 500% after its Phase 3 HOPE-3 trial showed Deramiocel, a cell therapy for Duchenne muscular dystrophy, met primary and secondary endpoints, improving heart function.
The results reversed a July 2024 FDA rejection that had caused a sharp decline.
The company launched a public equity offering to capitalize on the momentum.
Meanwhile, silver prices hit a record high above $58 per ounce, driven by strong industrial demand, especially from solar energy, with analysts predicting continued growth into 2026 or 2027.
NEXTDC signed a deal with OpenAI to build a hyperscale AI campus in Sydney, boosting its shares 8%.
The World Gold Council forecasts gold volatility in 2026, with a likely 5% to 15% rise amid safe-haven demand, though risks remain from inflation and geopolitical tensions.
Critical Resources advanced exploration at its Cap Burn and Amoco projects, with promising drill results and regulatory progress.
Las acciones de Capricor Therapeutics se dispararon un 500% después de que su medicamento cumplió con los objetivos clave del ensayo, revirtiendo un revés anterior de la FDA.